Health Catalyst, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 8, 2024, by Health Catalyst, Inc. The filing discloses the publication of the company's J.P. Morgan 2024 Healthcare Conference presentation, which includes preliminary results for the fourth quarter and full year of 2023, along with forward-looking commentary.
Key Financial Metrics and Performance
- 2023 Revenue and Adjusted EBITDA: Preliminary results for Q4 and full-year 2023 are reported to be at or above the midpoint of the company's guidance range.
- 2023 Bookings: Preliminary results are described as encouraging.
- 2023 Net New DOS Subscription Clients: Performance is expected to be in line with expectations.
- 2023 Dollar-Based Retention Rate: Estimated at approximately 100%, which is below the forecasted range of 102% to 110%.
- 2024 Adjusted EBITDA: Management now anticipates approximately $25 million.
- 2025 Adjusted EBITDA Margin: Target is set at 10% or greater.
The filing does not provide specific values for GAAP net loss, cash flow, debt, or liquidity, noting that stock-based compensation and other items make forecasting net loss difficult.
Material Changes and Operational Updates
The primary material change noted is the downward revision of the 2023 Dollar-Based Retention Rate estimate. Management attributes this to timing delays with a few larger Tech-Enabled Managed Services (TEMS) expansion opportunities, which are still anticipated to be signed in the near future. Despite this, the company reports continued optimism regarding its pipeline and momentum entering 2024.
Guidance, Outlook, and Risks
Management expects an improvement in 2024 net new DOS Subscription Client bookings and Dollar-Based Retention Rate metrics relative to 2023, driven by growth reacceleration and an improving operating environment. The company has not reconciled Adjusted EBITDA guidance to GAAP net loss due to uncontrollable variables like stock-based compensation. Standard forward-looking statement risks apply, including the possibility that actual results may differ materially from expectations due to factors beyond the company's control.
Investor Verification Checklist
- Verify the specific preliminary revenue and Adjusted EBITDA figures in the attached J.P. Morgan presentation (Exhibit 99.1).
- Confirm the status and expected closing dates of the delayed Tech-Enabled Managed Services (TEMS) expansion opportunities.
- Review the detailed reconciliation of Adjusted EBITDA to GAAP net loss in the most recent Form 10-K or 10-Q to understand the impact of non-cash items.
- Monitor subsequent filings for updates on the 2024 Adjusted EBITDA target of $25 million.